

REVIEW ARTICLE

UPI JOURNAL OF CHEMICAL AND LIFE SCIENCES (UPI-JCLS)

ISSN: 2581-4648 (An International online Peer Reviewed Open Access Journal)

www.uniquepubinternational.com



Published by Unique Pub International (UPI)

REGULATORY REQUIREMENTS FOR GENERIC DRUGS USED IN CANADA: A COMPREHENSIVE REVIEW

SAI PUSHKARA PAGADALA*, RAMA KRISHNA GARLAPATI, M.V. NAGABHUSHANAM, BANDI PAVITHRA, BANDELA SUMASRI

Department of Pharmaceutical Regulatory Affairs, Hindu College of Pharmacy, Amaravati Road, Guntur.

*Corresponding Author

Sai Pushkara Pagadala

Received: 04 05 2026 Revised: 11 05 2026 Accepted: 16 06 2026

Abstract

Generic drugs play a critical role in healthcare systems worldwide by improving patient access to affordable medications while maintaining the same standards of quality, safety, and efficacy as innovator products. In Canada, the regulation of generic drugs is governed by the Food and Drugs Act and the Food and Drug Regulations under the oversight of Health Canada. The approval process for generic drugs involves rigorous scientific evaluation to ensure pharmaceutical equivalence and bioequivalence with a Canadian Reference Product (CRP). Manufacturers seeking approval must submit an Abbreviated New Drug Submission (ANDS) containing comprehensive data on quality, safety, efficacy, and bioavailability. Recent regulatory developments have focused on clarifying the eligibility criteria for the ANDS pathway, particularly concerning therapeutically active components, pharmaceutical equivalence, and alternative Canadian Reference Products. The proposed amendments aim to improve access to high-quality generic medicines while enhancing transparency, consistency, and regulatory efficiency. Special considerations apply to radiopharmaceuticals, biologics, labelling requirements, data protection provisions, and patent linkage regulations. The Notice of Compliance (NOC) and Drug Identification Number (DIN) issued by Health Canada serve as essential regulatory approvals authorizing market entry. This review comprehensively examines the Canadian regulatory framework governing generic drugs, including legislative requirements, review processes, pharmaceutical equivalence standards, Canadian Reference Products, safety and effectiveness considerations, data protection mechanisms, and recent regulatory reforms. Understanding these requirements is essential for pharmaceutical manufacturers, regulatory professionals, healthcare practitioners, and policymakers involved in generic drug development and approval in Canada. The evolving regulatory landscape continues to support innovation while ensuring the availability of safe, effective, and affordable generic medicines for Canadian patients.

Keywords: Generic drugs, Health Canada, Abbreviated New Drug Submission, Canadian Reference Product, Pharmaceutical Equivalence, Bioequivalence, Drug Regulation, Notice of Compliance.

Copyright:© 2026 The author(s). This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

**INTRODUCTION**

The increasing demand for affordable healthcare has significantly enhanced the importance of generic medicines in modern healthcare systems. Generic drugs provide cost-effective therapeutic alternatives to innovator or brand-name drugs while maintaining equivalent quality, safety, and efficacy profiles. The availability of generic medicines contributes substantially to reducing healthcare expenditures, improving patient access to essential medications, and promoting competition within pharmaceutical markets [1,2].

A generic drug is defined as a pharmaceutical product that contains the same medicinal ingredient as an approved innovator drug in identical strength, dosage form, route of administration, and intended use. Although generic products may differ in non-medicinal ingredients such as excipients, preservatives, colorants, or manufacturing processes, these differences must not affect the safety, efficacy, or quality of the product compared with the reference drug [3].

In Canada, the regulation of generic drugs is primarily governed by the Food and Drugs Act and the Food and Drug Regulations. Health Canada, through the Health Products and Food Branch (HPFB), is responsible for evaluating and approving generic drug submissions. Before a generic drug can be marketed, manufacturers must demonstrate that the

product meets stringent regulatory standards concerning pharmaceutical equivalence, bioequivalence, quality, safety, and efficacy [4].

The Canadian regulatory framework emphasizes scientific rigor and patient protection. Generic drug manufacturers seeking marketing authorization typically follow the Abbreviated New Drug Submission (ANDS) pathway. This pathway enables approval based on comparison with an existing Canadian Reference Product rather than requiring extensive clinical efficacy studies, thereby reducing development costs and facilitating timely market access [5].

Recent amendments proposed by Health Canada have focused on modernizing generic drug regulations to reflect advances in pharmaceutical sciences and evolving regulatory practices. These reforms address issues related to therapeutically active components, pharmaceutical equivalence definitions, labelling requirements, data protection provisions, and alternative Canadian Reference Products [6].

This review provides a comprehensive overview of the regulatory requirements governing generic drugs in Canada, highlighting current regulations, approval pathways, scientific standards, and recent regulatory developments.

OVERVIEW OF GENERIC DRUGS

Generic drugs represent pharmaceutical products designed to be interchangeable with previously approved innovator drugs. Their development becomes possible following the expiration of patent protections and data exclusivity periods associated with the original product [2].

The principal characteristics of generic drugs include:

- Identical medicinal ingredient
- Same dosage form
- Same strength and concentration
- Same route of administration
- Comparable therapeutic effects
- Demonstrated bioequivalence to the reference product

Generic drugs offer significant economic benefits by reducing treatment costs and increasing medication accessibility. Numerous studies have demonstrated that approved generic medicines achieve therapeutic outcomes equivalent to those of their innovator counterparts while substantially reducing healthcare expenditures [3,7].

Health Canada requires manufacturers to provide evidence demonstrating that any differences in non-medicinal ingredients do not affect product performance or patient safety [4].

Regulatory Framework Governing Generic Drugs in Canada

The regulatory oversight of generic drugs in Canada is established through several legislative instruments, including:

1. Food and Drugs Act

The Food and Drugs Act serves as the primary legislation regulating pharmaceutical products marketed in Canada. It establishes legal requirements relating to product safety, efficacy, quality, manufacturing standards, labelling, advertising, and post-marketing surveillance [4].

2. Food and Drug Regulations

The Food and Drug Regulations provide detailed regulatory requirements governing drug development, approval, manufacturing, distribution, and post-market monitoring. Generic drugs must comply with all applicable provisions under these regulations before receiving authorization for marketing [5].

3. Controlled Drugs and Substances Act

Certain generic drugs containing controlled substances must additionally comply with requirements established under the Controlled Drugs and Substances Act and related regulations, including the Narcotic Control Regulations [8].

4. Patent Act and PM (NOC) Regulations

Patent protection mechanisms and the Patented Medicines (Notice of Compliance) Regulations establish procedures for balancing generic market entry with intellectual property protection for innovator products [9].

HEALTH CANADA REVIEW PROCESS FOR GENERIC DRUG SUBMISSIONS

The Health Products and Food Branch (HPFB) conducts comprehensive scientific reviews of generic drug submissions to ensure compliance with Canadian regulatory requirements [4].

The review process includes:

Evaluation of Quality

Manufacturers must submit detailed information concerning:

- Drug substance characteristics
- Manufacturing processes
- Analytical methods
- Stability studies
- Packaging systems
- Quality control procedures

Health Canada evaluates whether the product consistently meets predefined quality standards [10].

Evaluation of Safety

Safety assessments include:

- Toxicological considerations
- Impurity profiles
- Risk-benefit analysis
- Post-marketing safety information

The objective is to ensure that potential risks do not outweigh anticipated benefits [11].

Evaluation of Efficacy

For generic products, efficacy is generally established through demonstration of bioequivalence rather than extensive clinical trials [5].

Review of Product Information

Health Canada reviews:

- Product labels
- Package inserts
- Product monographs
- Consumer information leaflets

These materials must accurately communicate benefits, risks, indications, and usage instructions [4].

NOTICE OF COMPLIANCE (NOC) AND DRUG IDENTIFICATION NUMBER (DIN)

Following successful review, Health Canada issues:

Notice of Compliance (NOC)

The NOC represents formal authorization permitting marketing of the drug in Canada [4].

Drug Identification Number (DIN)

The DIN is a unique eight-digit number assigned to approved drug products marketed in Canada. It serves as an official identifier and confirms regulatory approval [12].

Both approvals are required before commercial distribution can commence.

CANADIAN REFERENCE PRODUCT (CRP)

A Canadian Reference Product (CRP) is fundamental to the generic drug approval process [5].

According to the Food and Drug Regulations, a CRP may be:

1. A drug marketed in Canada by the innovator.
2. An alternative drug acceptable to the Minister when the original product is no longer marketed.
3. Another acceptable comparator demonstrating pharmaceutical and bioavailability equivalence [6].

The CRP serves as the benchmark against which generic products are compared for:

- Pharmaceutical equivalence
- Bioequivalence
- Therapeutic equivalence

Recent Health Canada consultations have proposed clarifying circumstances under which alternative CRPs may be used when reference products acquire dormant status [13].

ABBREVIATED NEW DRUG SUBMISSION (ANDS)

The ANDS pathway provides an expedited mechanism for generic drug approval [5].

Manufacturers utilizing the ANDS pathway must demonstrate:

- Pharmaceutical equivalence
- Bioequivalence
- Product quality
- Compliance with Good Manufacturing Practices (GMP)

The ANDS pathway eliminates the need for extensive clinical efficacy studies because therapeutic effectiveness has already been established by the innovator product [6].

Components of an ANDS

An ANDS typically contains:

Administrative Information

- Manufacturer details
- Submission forms
- Regulatory declarations

Quality Information

- Drug substance information
- Drug product specifications
- Manufacturing data

Bioequivalence Data

- Pharmacokinetic studies
- Comparative bioavailability studies

Labelling Information

- Product monographs
- Package labels

The ANDS pathway significantly reduces development costs and accelerates market entry for generic medicines [5].

PHARMACEUTICAL EQUIVALENCE

Pharmaceutical equivalence is a fundamental requirement for generic drug approval [6].

A pharmaceutically equivalent drug must:

- Contain identical medicinal ingredients
- Have identical dosage strength
- Use comparable dosage forms
- Meet comparable quality specifications

Differences in non-medicinal ingredients are permissible provided they do not alter therapeutic performance [4].

The proposed amendments clarify pharmaceutical equivalence definitions for different classes of drugs, including radiopharmaceutical products [6].

BIOEQUIVALENCE REQUIREMENTS

Bioequivalence demonstrates that the generic drug delivers the active ingredient to the systemic circulation at a rate and extent similar to the reference product [14].

Typical bioequivalence studies assess:

- Maximum plasma concentration (C_{max})
- Area under the curve (AUC)
- Time to maximum concentration (T_{max})

Regulatory acceptance generally requires the 90% confidence intervals for C_{max} and AUC ratios to fall within predefined equivalence limits [14].

Bioequivalence studies are essential because they provide evidence supporting therapeutic interchangeability between generic and innovator products.

THERAPEUTICALLY ACTIVE COMPONENT

Health Canada has proposed replacing the concept of identical medicinal ingredients with identical therapeutically active components for many generic products [6].

A therapeutically active component is defined as:

A medicinal ingredient excluding appended portions that cause the ingredient to exist as a salt, hydrate, or solvate [6].

This approach recognizes advances in pharmaceutical science and permits approval of products containing:

- Different salt forms
- Different hydrate forms
- Different solvate forms
- Different polymorphic forms

provided the therapeutically active component remains identical [6].

SCHEDULE C AND SCHEDULE D DRUGS

Schedule C Drugs

Schedule C includes radiopharmaceutical products.

Health Canada proposes retaining the existing ANDS eligibility criteria for these products because of their unique characteristics [6].

Schedule D Drugs

Schedule D includes biologic drugs.

Biologic products are excluded from the ANDS pathway because of their complexity and variability [15].

Instead, biosimilars must be approved through the New Drug Submission (NDS) pathway and demonstrate similarity to an approved reference biologic product [15].

SAFETY AND EFFECTIVENESS CONSIDERATIONS

Health Canada may request additional information whenever differences between the generic product and CRP raise concerns regarding safety or effectiveness [6].

Manufacturers may be required to demonstrate that:

- Any chemical differences are clinically insignificant.

- Therapeutic outcomes remain unchanged.
- Safety profiles remain acceptable.

These provisions strengthen regulatory oversight while allowing scientific flexibility in product development [6].

LABELLING REQUIREMENTS

Accurate labelling is essential for safe medication use [4].

Proposed amendments require labels to identify:

- Medicinal ingredient
- Therapeutically active component
- Dosage strength
- Route of administration
- Indications
- Warnings and precautions

When medicinal ingredients differ from therapeutically active components, both must be declared on the product label [6].

These requirements improve transparency and facilitate informed decision-making by healthcare professionals and patients.

DATA PROTECTION PROVISIONS

Canada's data protection framework protects innovative pharmaceutical products from unfair commercial use of proprietary clinical and preclinical data [16].

The proposed amendments refine the definition of "variation" to include:

- Enantiomers
- Polymorphs
- Hydrates
- Solvates
- Salt forms

These clarifications enhance consistency between data protection provisions and updated definitions of therapeutically active components [6].

PATENT PROTECTION AND PM (NOC) REGULATIONS

The Patented Medicines (Notice of Compliance) Regulations establish procedures linking drug approval with patent protection [9].

Generic manufacturers seeking approval must:

1. Obtain patent owner consent;
2. Await patent expiry; or
3. File a Notice of Allegation challenging patent validity or infringement.

These regulations balance incentives for pharmaceutical innovation with timely generic market entry [9].

Dormant Status and Alternative Canadian Reference Products

Health Canada recently clarified the implications of dormant status in the Drug Product Database [13].

A drug may receive dormant status when:

- It has not been marketed for twelve consecutive months.
- The manufacturer notifies Health Canada of discontinued sales.

Under proposed amendments, dormant status may serve as evidence that a product is no longer marketed in Canada, thereby permitting use of alternative CRPs under specific circumstances [13].

This flexibility may improve generic drug availability while maintaining scientific standards.

IMPACT OF REGULATORY REFORMS ON GENERIC DRUG DEVELOPMENT

The proposed amendments offer several advantages:

Improved Access

More generic products may qualify for approval through the ANDS pathway [6].

Regulatory Clarity

Definitions of pharmaceutical equivalence and therapeutically active components become clearer and more predictable [6].

Enhanced Transparency

Labelling requirements provide better information for healthcare professionals and consumers [6].

Scientific Modernization

Regulations reflect advances in pharmaceutical chemistry and formulation science [17].

Increased Competition

Facilitating generic approvals may contribute to lower healthcare costs and increased patient access [18].

CHALLENGES IN GENERIC DRUG REGULATION

Despite the strengths of the Canadian framework, challenges remain:

- Complex patent disputes
- Global supply chain vulnerabilities
- Manufacturing quality concerns
- Emerging technologies
- Biosimilar regulation
- Regulatory harmonization

Addressing these challenges will require continued collaboration among regulators, manufacturers, healthcare professionals, and policymakers [19].

FUTURE PERSPECTIVES

Future regulatory developments may focus on:

- Greater international harmonization
- Digital regulatory submissions
- Advanced bioequivalence methodologies
- Real-world evidence integration
- Artificial intelligence-supported reviews
- Enhanced post-marketing surveillance systems

These innovations have the potential to improve regulatory efficiency while maintaining high standards of public health protection [20].

CONCLUSION

Generic drugs represent an essential component of Canada's healthcare system by improving medication accessibility and affordability while maintaining rigorous standards of safety, efficacy, and quality. Health Canada's regulatory framework ensures that generic medicines undergo comprehensive scientific evaluation through the ANDS pathway before receiving market authorization. Recent regulatory reforms involving pharmaceutical equivalence, therapeutically active components, Canadian Reference Products, labelling requirements, and data protection provisions reflect the evolving nature of pharmaceutical science and regulatory practice. These changes aim to increase transparency, improve access to generic medicines, and promote regulatory consistency while safeguarding public health. Continued modernization of the Canadian generic drug regulatory framework will be crucial in supporting innovation, competition, and patient access to high-quality medicines in the future.

ABBREVIATIONS

ANDS – Abbreviated New Drug Submission

CRP – Canadian Reference Product

DIN – Drug Identification Number

GMP – Good Manufacturing Practice

HPFB – Health Products and Food Branch

NDS – New Drug Submission

NOC – Notice of Compliance

PM (NOC) – Patented Medicines (Notice of Compliance)

RIAS – Regulatory Impact Analysis Statement

AUTHOR CONTRIBUTIONS

Vidya Sagar Pasumarty conceptualized the review topic, conducted the literature survey, organized the content, and drafted the manuscript. Anupkumar Dilipkumar Thakkar contributed to literature collection, critical review of the scientific content, and manuscript editing. Leena Alla contributed to scientific evaluation, manuscript revision, and final approval of the article. All authors read and approved the final manuscript

CONFLICT OF INTEREST

The authors declare no conflict of interest.

FUNDING

No external funding was received for this study.

AUTHOR CONTRIBUTIONS

All authors contributed equally to the conception, literature review, drafting, revision, and approval of the manuscript.

REFERENCES

1. Health Canada. Generic drugs: Questions and answers [Internet]. Ottawa: Government of Canada; 2024 [cited 2026 Jun 26].
2. Canadian Generic Pharmaceutical Association. The role of generic medicines in healthcare. Ottawa: CGPA; 2023.
3. World Health Organization. Generic medicines: Interchangeability and quality assurance. Geneva: WHO; 2022.
4. Health Canada. Guidance document: Management of drug submissions and applications. Ottawa: Government of Canada; 2024.
5. Government of Canada. Food and Drug Regulations (C.R.C., c. 870). Ottawa: Government of Canada; 2024.
6. Government of Canada. Regulations amending the Food and Drug Regulations (generic drugs). Canada Gazette. 2019;153(13):1-28.
7. Dunne S, Shannon B, Dunne C, Cullen W. A review of the differences and similarities between generic drugs and their originator counterparts. BMC Pharmacol Toxicol. 2013;14:1-9.
8. Government of Canada. Controlled Drugs and Substances Act. Ottawa: Government of Canada; 2024.
9. Government of Canada. Patented Medicines (Notice of Compliance) Regulations. Ottawa: Government of Canada; 2024.
10. International Council for Harmonisation. ICH Q8 Pharmaceutical Development. Geneva: ICH; 2022.
11. International Council for Harmonisation. ICH Q9 Quality Risk Management. Geneva: ICH; 2023.
12. Health Canada. Drug Identification Number (DIN): Overview. Ottawa: Government of Canada; 2024.
13. Fasken. The danger of dormant status: Health Canada clarifies Canadian reference product definition. Toronto: Fasken LLP; 2024.
14. Health Canada. Conduct and analysis of comparative bioavailability studies. Ottawa: Government of Canada; 2023.
15. Health Canada. Guidance for sponsors: Information and submission requirements for biosimilar biologic drugs. Ottawa: Government of Canada; 2024.
16. Government of Canada. Data protection under the Food and Drug Regulations. Ottawa: Government of Canada; 2024.
17. International Council for Harmonisation. ICH M4 Organisation of the Common Technical Document. Geneva: ICH; 2022.
18. OECD. Pharmaceutical policies in OECD countries. Paris: OECD Publishing; 2023.
19. World Health Organization. Regulatory systems strengthening for medical products. Geneva: WHO; 2023.
20. International Pharmaceutical Regulators Programme. Future directions in generic drug regulation. Geneva: IPRP; 2024.